In VivoBiopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso
In VivoIn the top alliance by deal value, Zealand Pharma entered into a global collaboration and license agreement with Roche to develop petrelintide, Zealand’s amylin analog as a foundational therapy for we
ScripMerger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu
Pink SheetThe US Food and Drug Administration’s newly revised stand on testosterone labeling for cardiovascular risk is the visible tip of the metaphorical iceberg of years of effort that went into evaluating a